IN2013CN01129A - - Google Patents

Download PDF

Info

Publication number
IN2013CN01129A
IN2013CN01129A IN1129CHN2013A IN2013CN01129A IN 2013CN01129 A IN2013CN01129 A IN 2013CN01129A IN 1129CHN2013 A IN1129CHN2013 A IN 1129CHN2013A IN 2013CN01129 A IN2013CN01129 A IN 2013CN01129A
Authority
IN
India
Prior art keywords
determining
level
colorectal cancer
diagnosing
detecting
Prior art date
Application number
Other languages
English (en)
Inventor
Leah Jane Cosgrave
Bruce Tabor
Tony W Burgess
Edouard Collins Nice
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Publication of IN2013CN01129A publication Critical patent/IN2013CN01129A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IN1129CHN2013 2010-07-14 2011-07-14 IN2013CN01129A (pm)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
PCT/AU2011/000895 WO2012006681A1 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Publications (1)

Publication Number Publication Date
IN2013CN01129A true IN2013CN01129A (pm) 2015-07-31

Family

ID=45468816

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1129CHN2013 IN2013CN01129A (pm) 2010-07-14 2011-07-14

Country Status (13)

Country Link
US (2) US20130345322A1 (pm)
EP (2) EP2829881B1 (pm)
JP (1) JP6061344B2 (pm)
CN (2) CN103140760B (pm)
AU (1) AU2011279555B2 (pm)
BR (1) BR112013000745B1 (pm)
DK (1) DK2829881T3 (pm)
ES (1) ES2653646T3 (pm)
IN (1) IN2013CN01129A (pm)
NO (1) NO2829881T3 (pm)
PT (1) PT2829881T (pm)
RU (1) RU2013103995A (pm)
WO (1) WO2012006681A1 (pm)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2829881T3 (pm) 2010-07-14 2018-01-20
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
TR201902555T4 (tr) 2012-08-09 2019-03-21 Ct Hospitalier Universitaire Toulouse Kalp yetmezliği tanısı.
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
SG11201608053PA (en) * 2014-03-28 2016-10-28 Applied Proteomics Inc Protein biomarker profiles for detecting colorectal tumors
TR201909951T4 (tr) * 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
CN106191215B (zh) 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
WO2016180335A1 (en) * 2015-05-12 2016-11-17 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
CN113825440B (zh) * 2018-10-23 2022-10-18 布莱克索恩治疗公司 用于对患者进行筛查、诊断和分层的系统和方法
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
KR102769007B1 (ko) * 2019-03-01 2025-02-14 어드밴스드 마커 디스커버리 에스.엘. 대장암 및/또는 이의 전암 단계 진단을 위한 단백질 시그니처
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
WO2021097327A1 (en) * 2019-11-13 2021-05-20 University Of Virginia Patent Foundation Treatment of clostridium difficile infections
EP3835789A1 (en) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Biomarker panel for diagnosing colorectal cancer
WO2022130597A1 (ja) * 2020-12-18 2022-06-23 国立大学法人東北大学 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム
CA3216160A1 (en) * 2021-04-20 2022-10-27 Trevor Lockett Biomarkers for colorectal cancer
US20250035631A1 (en) * 2021-08-11 2025-01-30 Vision Tech Bio Pty Ltd Method of detecting adenoma
WO2023128419A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용
WO2023128429A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 진행 선종의 선별 검사 방법 및 그 응용
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
CN119688988A (zh) * 2024-11-25 2025-03-25 中国医学科学院肿瘤医院 Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US20040157278A1 (en) * 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
WO2008073660A1 (en) 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
CA2676227A1 (en) 2007-02-12 2008-08-21 The Johns Hopkins University Early detection and prognosis of colon cancers
EP2472264B1 (en) * 2007-02-27 2015-11-25 SentoClone International AB Multiplex detection of tumour cells using a panel of agents binding to extracellular markers
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
EP2145190A1 (en) * 2007-05-10 2010-01-20 Roche Diagnostics GmbH Use of timp-1 as a marker for colorectal cancer
US8492328B2 (en) * 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
EP2171470A2 (en) * 2007-06-04 2010-04-07 Diagnoplex Biomarker combinations for colorectal cancer
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
US20110059464A1 (en) * 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
EP2370086A2 (en) * 2008-12-01 2011-10-05 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
EP2370813A4 (en) * 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER
US9354233B2 (en) * 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
NO2829881T3 (pm) * 2010-07-14 2018-01-20

Also Published As

Publication number Publication date
BR112013000745A2 (pt) 2016-05-24
WO2012006681A1 (en) 2012-01-19
US20170205414A1 (en) 2017-07-20
EP2829881A2 (en) 2015-01-28
AU2011279555B2 (en) 2016-10-20
CN103140760A (zh) 2013-06-05
EP2593795A1 (en) 2013-05-22
JP2013533977A (ja) 2013-08-29
JP6061344B2 (ja) 2017-01-18
US20130345322A1 (en) 2013-12-26
AU2011279555A1 (en) 2013-01-31
US10877039B2 (en) 2020-12-29
CN103140760B (zh) 2016-01-27
EP2829881B1 (en) 2017-08-23
EP2593795A4 (en) 2014-01-22
DK2829881T3 (en) 2017-12-04
CN105755112B (zh) 2019-06-07
ES2653646T3 (es) 2018-02-08
EP2829881A3 (en) 2015-05-13
BR112013000745B1 (pt) 2021-02-02
PT2829881T (pt) 2017-11-29
CN105755112A (zh) 2016-07-13
NO2829881T3 (pm) 2018-01-20
RU2013103995A (ru) 2014-08-20

Similar Documents

Publication Publication Date Title
IN2013CN01129A (pm)
MX357119B (es) Microarn plasmáticos para la detección de cáncer colorrectal temprano.
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
MX340453B (es) Biomarcadores para cancer de pulmon.
MX341517B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
HK1259001A1 (zh) 癌症的预後和诊断方法
PH12012500850A1 (en) Methods for diagnosing irritable bowel syndrome
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
NZ624816A (en) Ratio based biomarkers and methods of use thereof
PH12013500544A1 (en) Breast cancer diagnostics
MX2011013243A (es) Marcadores de riesgo para enfermedad cardiovascular.
EA030186B9 (ru) Способ проведения количественных анализов
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
EA201370063A1 (ru) Фосфолипидом рака
IN2014CN01787A (pm)
MX357429B (es) Predictores para el tratamiento del cáncer.
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2012178188A3 (en) Molecular diagnostic panel of eosinophilic gastrointestinal disorders
WO2010053816A3 (en) Biomarkers for diagnosis of breast cancer
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis